Patient ID	Patient Name		Birth Date	Sex	Age
C7028846-0006399	TESTING, PHLFD-ABNORMAL		1991-05-15	F	33
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
X100498312	X100498312	unknown			
Account Information		**Collected**			
C7028846 DLMP Rochester		07 May 2025 08:20			

BCR/ABL1-like B-ALL pnl, Diag, FISH

Result Summary
MCR

Abnormal

Interpretation
MCR

The result is abnormal and indicates 72% of nuclei have an IKZF1 deletion.

Deletion of the IKZF1 gene, in the absence of an ERG deletion, has been associated with poor outcome and high risk of relapse in B-lymphoblastic leukemia/lymphoma (Mullighan et al., N Engl J Med. 360:471–480, 2009).

A hematologic chromosomal microarray (test CMAH) can be performed to evaluate for the presence of submicroscopic abnormalities such as ERG deletions. Results from the microarray study may alter the interpretation of these results. If interested, please call the laboratory to inquire whether there is sufficient material from the current specimen to carry out this test (507–266–0790).

Result Table
MCR

Abnormality Name	Result	Abn%	Cutoff%
1q25(ABL2 sep)	Normal		<10.0
5q32(PDGFRB sep)	Normal		<15.0
9p24.1(JAK2 sep)	Normal		<10.0
9q34(ABL1 sep)	Normal		<15.0
Xp22.33/ Yp11.32(3'CRLF2retention,5 'loss)	Normal		<10.0
-7p12.2(IKZF1x1,Cep7x2)	Abnormal	72	<15.0

Result
MCR

nuc ish (IKZF1x1,CEP7x2)[72/100]

Reason for Referral
MCR

r/o Ph-like B-cell ALL

Specimen
MCR

Bone Marrow

Source
MCR

Left iliac crest

Method
MCR

Locus and probes	[Strategy;#Nuclei;Vendor]
Xp22.33/Yp11.32(3'CRLF2,5'CRLF2)	[BAP;100;C]
1q25(3'ABL2,5'ABL2)	[BAP;100;LDT]
5q32(3'PDGFRB,5'PDGFRB)	[BAP;100;LDT]
7p12.2(IKZF1), 7CEN(CEP7)	[COPY#;100;AT]
9p24(5'JAK2,3'JAK2)	[BAP;100;LDT]
9q34(5'ABL1,3'ABL1)	[BAP;100;LDT]

Probe strategies include:
BAP=break-apart probe;
COPY#=region gain and loss.
Scoring Method: Manual

Probe vendors include:
LDT = Mayo Clinic Developed
AT = Agilent Technologies (Santa Clara, CA)
C = Cytocell, Inc. (Cambridge, UK)

Disclaimer
MCR

Applicable to Analyte Specific Reagent (ASR) and Laboratory Developed Tests (LDT). This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. This FISH test does not rule out other chromosome abnormalities.

Released By
MCR

Xinjie Xu, Ph.D.

Received: 13 May 2025 10:52 **Reported:** 21 May 2025 14:20

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292